TetraLogic Pharmaceuticals Announces Clinical Data on Birinapant to be Presented at the 56th Annual American Society of Hematology Annual Meeting
04 déc. 2014 07h30 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Dec. 4, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that two abstracts related to clinical data on birinapant will be presented at the...
TetraLogic to Participate in Two Conferences in December
02 déc. 2014 07h30 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Dec. 2, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that company management will participate in the following conferences in New York...
TetraLogic Pharmaceuticals Announces Results of Preclinical Studies in Hepatitis B
10 nov. 2014 08h00 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Nov. 10, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced additional results from preclinical studies that demonstrated the ability of the...
TetraLogic Pharmaceuticals Announces Appointment of Mary Ann Gray, Ph.D. and Mr. Michael D. Kishbauch as New Directors
07 nov. 2014 11h10 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Nov. 7, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the appointment of Mary Ann Gray, Ph.D. and Mr. Michael D. Kishbauch as Class I...
TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update
05 nov. 2014 16h36 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Nov. 5, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic Pharmaceuticals to Host Investor Forum on November 10, 2014
03 nov. 2014 07h30 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Nov. 3, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that the company will host a live audio webcast in conjunction with its Investor...
TetraLogic Pharmaceuticals to Present Data From Pre-Clinical Studies With Hepatitis B at the 2014 International Meeting on Molecular Biology of Hepatitis B Viruses
27 août 2014 07h30 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Aug. 27, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data from the preclinical studies that provide the rationale for SMAC-mimetics...
TetraLogic Announces Closing of $47 Million Convertible Senior Notes Offering
24 juin 2014 07h30 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., June 24, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) (the "Company" ) announced the closing of its previously-announced offering of $47 million...
TetraLogic Announces Pricing of $47 Million Offering of Convertible Notes
17 juin 2014 21h05 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., June 17, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) (the "Company") announced the pricing of its offering of $47 million in aggregate principal amount...
TetraLogic Pharmaceuticals Announces Conference Call With Dr. Marc Pellegrini of the Walter and Eliza Hall Institute of Medical Research to Discuss TetraLogic Infectious Disease Program
13 juin 2014 07h30 HE
|
TetraLogic Pharmaceuticals
MALVERN, Pa., June 13, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) ("Company") today announced that it will host a conference call and live audio webcast on Monday,...